Nektar Therapeutics (NKTR) PT Raised to $63 at Evercore ISI; 'Highlights from 4Q earnings call'
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $67.10 -1.84%
Rating Summary:
20 Buy, 8 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
20 Buy, 8 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
Evercore ISI raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $63.00 (from $31.00) while maintaining a In Line rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
- Envista Holdings Corp. (NVST) PT Lowered to $27 at UBS, Neutral Rating Maintained
- Anthropic delays planned IPO from October to November - WSJ
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
